Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/23119
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaral, Rathindranath-
dc.date.accessioned2013-11-08T05:08:19Z-
dc.date.available2013-11-08T05:08:19Z-
dc.date.issued2005-05-
dc.identifier.issn0975-1009 (Online); 0019-5189 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/23119-
dc.description389-406en_US
dc.description.abstractEffective cancer treatment to prevent the tumor growth as well as to stop its recurrence is the dream of oncologists. Currently available therapeutic measures like, radiotherapy and chemotherapy, often suffer from severe toxicity and lack of specificity of the drug towards tumor cells. Another promising approach is the 'immunotherapy', in which either the immune system is activated by tumor vaccine to combat the tumor growth or antitumor antibodies can be used. Vaccination can stimulate humoral, cellular and innate immune systems to generate various effector molecules, like antibody, cytotoxic T cells, cytokines etc. In antigen specific immunotherapy, the immune system can be stimulated actively by antigen based tumor vaccine to kill only those tumor cells, having expression of the particular tumor associated antigen. Different experimental, preclinical and clinical studies have proved that generated immune responses are effective to restrict the tumor growth. Useful strategies of antigen specific immunotherapy and outcome of various laboratory and clinic based studies are discussed.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJEB Vol.43(05) [May 2005]en_US
dc.subjectAntibodyen_US
dc.subjectAntigenen_US
dc.subjectImmunotherapyen_US
dc.subjectTumoren_US
dc.subjectVaccineen_US
dc.titleTumor vaccine: Current trends in antigen specific immunotherapyen_US
dc.typeArticleen_US
Appears in Collections:IJEB Vol.43(05) [May 2005]

Files in This Item:
File Description SizeFormat 
IJEB 43(5) 389-406.pdf5.51 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.